Table 1. Integrin profile of prostate tissue and peripheral blood-derived CD133+ cells, prostate cancer cell lines and the mononuclear cells of control and prostate cancer patients (mean ± SEM).
| Integrin name | Prostate-derived CD133+ cells (%) |
Peripheral blood-derived CD133+ cells (%) |
PCa cell lines (%) |
Mononuclear cells (%) |
||||
|---|---|---|---|---|---|---|---|---|
| Controls | PCa patients | Controls | PCa patients | PC-3 | DU-145 | Controls | PCa patients | |
| α1 | 15.0 ± 5.6 | 85.0 ± 3.2 | 18.0 ± 4.6 | 94.0 ± 4.1# | 89.0 ± 3.1 | 90.0 ± 2.3 | 91.0 ± 4.3 | 90.0 ± 2.6 |
| β1 | 27.0 ± 7.4 | 95.0 ± 1.8* | 21.0 ± 5.5 | 97.0 ± 1.5# | 90.0 ± 5.6 | 89.0 ± 6.1 | 93.0 ± 3.2 | 94.0 ± 1.7 |
| αv β3 | 11.0 ± 2.7 | 40.0 ± 8.6 | 10.0 ± 3.7 | 93.0 ± 3.6# | 50.0 ± 4.5 | 49.0 ± 3.6 | 70.0 ± 4.7 | 68.0 ± 5.1 |
| αv β5 | 10.0 ± 3.1 | 10.0 ± 3.2 | 12.0 ± 2.2 | 95.0 ± 4.1# | 52.0 ± 3.8 | 51.0 ± 3.4 | 72.0 ± 5.1 | 71.0 ± 7.6 |
| α2β1 | 8.0 ± 2.6 | 95 .0± 1.3 | 13.0 ± 3.6 | 90.0 ± 1.6# | 58.0 ± 5.6 | 54.0 ± 2.6 | 65.0 ± 6.1 | 60.0 ± 3.2 |
| α4β1 | 10.0 ± 2.3 | 17.0 ± 4.1 | 17.0 ± 4.7 | 30.0 ± 3.2 | 61.0 ± 2.4 | 60.0 ± 6.5 | 79.0 ± 4.1 | 80.0 ± 2.6 |
| β2 | 7.0 ± 4.2 | 20.0 ± 5.6 | 10.0 ± 4.6 | 26.0 ± 3.1 | 41.0 ± 2.9 | 44.0 ± 8.6 | 40.0 ± 5.3 | 23.0 ± 6.7 |
Abbreviation: PCa, Prostate cancer.
*
P < 0.05,
#
P < 0.01, compared with the control.